Programmed cell death 1 (PD-1), and its ligand programmed cell death-ligand 1 (PD-L1), is important for tumor-immune escape. Expression PD-L1 was observed in various solid tumors, including breast cancer (BC). The aim of this study is to examine the expression of PD-1 in tumor infiltrating lymphocytes (TILs) and PD-L1 in tumor cells (TC) in BC cases, to analyze the association between PD-1 and PD-L1 expression and clinicopathological features, as well as to correlate their expression with overall survival (OS). This is a retrospective study that was conducted on 110 cases of BC. Immunohistochemistry was performed to evaluate PD-1 and PD-L1 expression in TILs and TC respectively. There was no significant association between PD-1expression in TILs and clinicopathological variables. The presence of PD-1+ TIL was positively associated with PDL-1 expression in tumor cells; however, this association was not statistically significant (p = 0.062). On the other hand, PD-L1 expression in TC was significantly associated with lymph node involvement (P <0.0001), advanced stage (P = 0.035), high grade (P <0.0001), high TIL (P = 0.009), and negative ER (P = 0.01). BC cases with PD-L1 expression had a significantly worse OS (HR = 0.201; 95% CI [0.048 - 0.112], p <0.000). PD-L1 expression was an independent prognostic factor in multivariate analysis (HR = 0.195; 95% CI [0.058 - 0.655], p =0.008). In conclusion, PD-L1 expression is associated with advanced tumor stage, aggressive subtypes of BC, lymphatic infiltration, and poor OS in BC.